VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors
April 27 2021 - 8:00AM
VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical
company committed to developing a new generation of medicines with
the potential to go beyond the current standard of care for
anxiety, depression and other central nervous system (“CNS”)
disorders, today announced the appointment of Joanne Curley, Ph.D.
to its Board of Directors (“Board”). Following the appointment of
Dr. Curley, VistaGen’s Board will be comprised of seven directors.
“Joanne brings more than 25 years of
pharmaceutical industry experience across numerous key operational
and therapeutic areas,” said Shawn Singh, Chief Executive Officer
of VistaGen. “Her track record of propelling seven products from
early development through regulatory approval is impressive and
reflects her extensive experience and understanding of the entire
life cycle of drug development. As we expand our business and
pursue our mission to improve mental health and well-being for
individuals in the U.S. and abroad, her tremendous leadership,
creativity and expertise will be invaluable to VistaGen.”
Dr. Curley is currently the Chief Development
Officer at Vera Therapeutics, Inc. Prior to joining Vera, Dr.
Curley spent 15 years with Gilead Sciences, during which time the
anti-viral portfolio grew from four to seventeen commercial
products. While at Gilead, Dr Curley led Project and Portfolio
Management with oversight of the development pipeline across four
therapeutic areas and was responsible for research and development
governance. Before Gilead, Dr. Curley worked as an aerosol
formulation scientist and subsequently as a project leader at
Nektar Therapeutics. She received a BSc in Physics and Chemistry
from Trinity College, Ireland, a Ph.D. in Polymer Science and
Engineering from the University of Massachusetts, Amherst and
completed a post-doctorate at Massachusetts Institute of Technology
and Harvard Medical School, focused on long-acting biodegradable
formulations.
About VistaGenVistaGen
Therapeutics is a biopharmaceutical company committed to developing
and commercializing innovative medicines with the potential to go
beyond the current standard of care for anxiety, depression, and
other CNS disorders. Each of VistaGen's three drug candidates has a
differentiated potential mechanism of action, has been
well-tolerated in all clinical studies to date and has therapeutic
potential in multiple CNS markets. For more information, please
visit www.VistaGen.com and connect with VistaGen on Twitter,
LinkedIn, and Facebook.
Forward Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of the federal securities laws. These forward-looking
statements involve known and unknown risks that are difficult to
predict and include all matters that are not historical facts. In
some cases, you can identify forward-looking statements by the use
of words such as “may,” “could,” “expect,” “project,” “outlook,”
“strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “strive,” “goal,” “continue,”
“likely,” “will,” “would” and variations of these terms and similar
expressions, or the negative of these terms or similar expressions.
Such forward-looking statements are necessarily based upon
estimates and assumptions that, while considered reasonable by us
and our management, are inherently uncertain. Our actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include, without limitation, risks and uncertainties
relating to delays in launching and/or conducting our planned
clinical trials, including delays due to the impact of the COVID-19
pandemic; fluctuating costs of materials and other resources
required to conduct our planned clinical and non-clinical trials;
continued uncertainty with respect to the COVID-19 pandemic; market
conditions; the impact of general economic, industry or political
conditions in the United States or internationally; adverse
healthcare reforms and changes of laws and regulations;
manufacturing and marketing risks, including risks related to the
COVID-19 pandemic, which may include, but are not limited to,
unavailability of or delays in delivery of raw materials for
manufacture of our CNS drug candidates and difficulty in initiating
or conducting clinical trials; inadequate and/or untimely supply of
one or more of our CNS drug candidates to meet demand; entry of
competitive products; and other technical and unexpected hurdles in
the development, manufacture and commercialization of our CNS drug
candidates; and the risks more fully discussed in the section
entitled "Risk Factors" in our most recent Annual Report on Form
10-K for the year ended March 31, 2020, and in our most recent
Quarterly Report on Form 10-Q for the quarter ended December 31,
2020, as well as discussions of potential risks, uncertainties, and
other important factors in our other filings with the U.S.
Securities and Exchange Commission (SEC). Our SEC filings are
available on the SEC’s website at www.sec.gov. You should not place
undue reliance on these forward-looking statements, which apply
only as of the date of this press release and should not be relied
upon as representing our views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements, other than as may be required by law. If we do update
one or more forward-looking statements, no inference should be made
that we will make additional updates with respect to those or other
forward-looking statements.
VistaGen Company ContactsMark McPartland / Mark
FlatherVistaGen Therapeutics Phone: (650) 577-3606Email:
IR@vistagen.com
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024